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Surgical Management of Medication-Related
Osteonecrosis of the Jaw Patients Related to
Dental Implants
Marco Nisi, DDS, Rossana Izzetti, DDS, PhD, Stefano Gennai, DDS, PhD,
Pierantonio Bellini, MD, OMFS,y Filippo Graziani, DDS, PhD, and Mario Gabriele, MD, DDS
Objectives: The aim of the present study is to report a case series of
patients with peri-implant medication-related osteonecrosis of the
jaw (MRONJ), in particular describing the onset of the condition
and surgical treatment outcome.
Material and Methods: Fifteen consecutive patients with clinical
diagnosis of peri-implant MRONJ were retrospectively included in the
study. The sample was stratified on the base of oral, pharmacological,
and general health variables. The number of affected implants was
recorded in all patients, and MRONJ staging applied. Surgical
treatment was performed with a standardized operative protocol,
involving implant removal, sequestrectomy, debridement of soft
tissue, and bone curettage. Follow-up evaluating surgical outcome
was performed at twelve months after surgery.
Results: in our study sample, patients were almost equally
distributed in terms of underlying diseases in osteoporotic and
oncologic patients. All MRONJ lesions were symptomatic, and
in 6 patients bone exposure was detected. 40 implants in total were
evaluated, with MRONJ being present around 29 implants. 12
patients were diagnosed with Stage III MRONJ, and 3 patients
with Stage II MRONJ. Surgical treatment leads to complete healing
in 86.7% of cases, with 100% success for maxillary MRONJ.
Conclusions: Surgical treatment seems to have a positive impact on
MRONJ treatment also in cases of peri-implant involvement.
However, monitoring and prevention are fundamental in patients
under pharmacological treatment with anti-resorptive/
antiangiogenic drugs, as peri-implant MRONJ can develop also
in absence of specific traumatic events.
Key Words: Dental implants, medical related osteonecrosis of the
jaw
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M edication-related osteonecrosis of the jaw (MRONJ) isdefined as a pathologic condition affecting the maxillary
bones associated to the treatment with anti-resorptive/antiangio-
genic drugs for the modulation of bone remodeling.1 Several
disorders contribute to dysregulation in bone activity, including
benign conditions (osteopenia, osteoporosis, and Paget disease) and
malignant diseases (multiple myeloma and bone metastases). Dif-
ferent therapeutic protocols, including per os or intravenous admin-
istration of anti-resorptive/antiangiogenic drugs, may thus be
applied.2
Among the adverse effects of antiresorptive drugs, Marx et al3
and Ruggiero et al1 initially described osteonecrosis of the jaws
associated to the administration of bisphosphonate (BP) therapy,
which was therefore defined as bisphosphonate-related osteonecro-
sis of the jaw (BRONJ).1,3 However, the increasing number of
osteonecrosis cases related to the administration of other antire-
sorptive and antiangiogenic drugs lead to a change in the definition
to MRONJ in 2014 by the American Association of Oral and
Maxillofacial Surgeons.1
Medication-related osteonecrosis of the jaw is currently defined
by the clinical presence of exposed bone or intraoral/extraoral
fistula present for more than 8 weeks, history of administration
of antiresorptive or antiangiogenic agents, and exclusion of previ-
ous head and neck radiation therapy or jaw metastases of
other tumors.
The etiology of MRONJ is still unknown, while pathogenesis
can be related to the fact that BPs and antiresorptive agents repress
osteoclast-mediated remodeling of bone through disruption of
intracellular pathways and inhibit angiogenesis.4 In the 2014
AAOMS position paper, risk factors for MRONJ were categorized
as drug-related, demographic, local, and systemic or genetic fac-
tors.1
Oral surgical procedures, including tooth extractions, implant
positioning, and periodontal surgery, in association with poor oral
hygiene, periodontal infections, abscesses, and mobile dental pros-
theses, have been recognized as risk factors concurring to the
development of MRONJ. Advanced age, smoking, corticosteroid
therapy, and coexisting pathologic conditions are considered sys-
temic factors favoring the development of MRONJ.5,6
While in literature it is reported the association of tooth extrac-
tions and MRONJ development, data is controversial on the rela-
tionship with implant placement. Two main facts seem to relate
MRONJ to implants, the first regarding the risk of osteonecrosis
associated to implant placement, and the second evaluating the
presence of the implants themselves as a risk factor for necrosis
development. A recent review by Giovannacci et al7 reports an
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association between the presence of implants at the development of
MRONJ. A potential role of patient general health condition and
duration of antiresorptive treatment has been claimed to influence
MRONJ development.7
Although some studies describe peri-implant MRONJ, currently
there is a lack of studies directly addressing the issue of surgical
treatment of this condition.2
The main aim of the present study was to describe the clinical
and radiographic characteristics of 15 cases of peri-implant
MRONJ. Its secondary objective was to evaluate the effectiveness
of surgical treatment of peri-implant MRONJ, describing our results
in terms of surgical outcome.
MATERIALS AND METHODS
Design of the Study and Sample
A sample of consecutive patients referring to the Unit of
Dentistry and Oral Surgery, University Hospital of Pisa (Pisa, Italy)
between January 2013 and December 2018 was retrospectively
enrolled in this study. All the patients were surgically treated for
this condition.
The study was conducted according to the criteria set by the
Declaration of Helsinki. Ethical committee approval regarding the
performance of the present retrospective study was obtained
through an exemption related to retrospective data collection.
Inclusion criteria were history of administration of antiresorp-
tive/antiangiogenic drugs and clinical diagnosis of peri-implant
MRONJ. The sample was stratified depending on systemic factors
and pharmacologic and local variables.
Systemic factors were considered:
 Comorbidities: smoking habit, diabetes, hypertension,
rheumatoid arthritis
 Underlying diseases requiring administration of antiresorp-
tive/antiangiogenic drugs: osteoporosis, metastatic breast
cancer, multiple myeloma, metastatic prostate cancer
Pharmacologic variables were related to the drug administrated,
both in terms of type of medication (zoledronate, alendronate,
ibandronate, neridronate, and denosumab) and of therapeutic pro-
tocol (length of therapy and cumulative dose).
The diagnosis of MRONJ was made by an experienced examiner
(MN) on the basis of clinical and radiographic examination (pan-
oramic radiograph and computed tomography (CT). In case of
uncertainty, an expert operator was consulted (MG).
Clinical evaluation allowed to determine local variables describ-
ing MRONJ characteristics, such as localization, presence of bone
exposure, suppuration, neurological symptoms (pain/paresthesia),
extra-oral fistulisation, and oro-antral communication.
Radiographic examination allowed determining the extension of
MRONJ and the possible presence of bone sequestrum. (Figs. 1 and 2)
Design of the Study and Sample
After the diagnosis of peri-implant MRONJ, all patients were
medically treated with a session of professional oral hygiene,
together with reinforcement of domestic oral hygiene and prescrip-
tion of 2% chlorhexidine mouthwash to be used twice daily for 14
days. Patients were also given amoxicillin with clavulanic acid (2 g/
day for 14 days) plus metronidazole (750 mg/day), and were
evaluated clinically two weeks later.
After medical treatment, resolution of the infection and pain relief
were obtained, while signs of complete healing were not observed.
Surgical approach was then performed. Pharmacological treatment
included a standardized administration protocol of antibiotics, with
the following scheme: 3 g of amoxicillin administrated preoperatively
and 2 g/day for two-weeks following surgery. In cases of allergy to
penicillin, oral azithromycin (1 g/day) was administrated.
All surgical interventions were performed under local anesthesia
by a single expert operator specialized in oral surgery. Surgical
treatment included removal of dental implants involved, seques-
trectomy, debridement of soft tissue, and curettage of bone. Resid-
ual sequestra were removed to ensure healing by primary intention.
At the end of the surgical intervention, the closure of the surgical
site was assured by suturing without mobilization of the flap with a
resorbable/non resorbable 5–0 suture thread; the removal of visible
FIGURE 1. Case presentation of peri-implant MRONJ in the right side of the
mandible. (A) Panoramic radiograph showing increased trabeculation around
dental implants located in the left side of the mandible. (B) Periodontal probing
around the implant located in position 4.3. Evident suppuration is present
around the implant, associated with increased probing pocket depth. (C)
Periodontal probing around the implant located in position 4.4. Marked
inflammation of peri-implant soft tissues with moderate swelling is observed.
FIGURE 2. Case presentation of peri-implant MRONJ in the left side of the
mandible. (A) Panoramic reconstruction from CT scan, showing the presence of
bone remodeling in correspondence of the implants located in the left side of
the mandible. In this patient, signs of delayed alveolar healing are also present in
the right side of the mandible. (B) Cross-section reconstructions of the left side
of the mandible. Despite the presence of beam hardening artifacts due to the
presence of metallic material, it is possible to highlight bone remodeling and
periosteal reaction in correspondence with the implants. (C–D) Clinical aspect
of the implants. Increased probing depth is present, and partial bone exposure
can be observed.
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suture was performed 14 days after surgery (Fig. 3). Histology was
performed on all removed bone samples.
We considered treatment outcome successful in cases of com-
plete healing of MRONJ, described as complete absence of exposed
necrotic bone, residual mucosal defect, fistulas and associated
symptoms (swelling and pain) at 12-month follow-up, as previously
reported by our group.8,9
RESULTS
Sample Characteristics
Fifteen patients, 13 women and 2 men with a mean age of
71.8 8.7 years (range 52–79 years), were included in the study
over a 5-year period. General sample characteristics are shown in
Supplemental Digital Content, Table 1, http://links.lww.com/SCS/
B191. In almost 50% of cases, administration of antiresorptive/
antiangiogenetic drugs was related to the treatment of osteoporosis.
Among osteoporotic patients, the majority of the sample (6 sub-
jects) was treated with alendronic acid (70 mg/week; cumulative
dose: 18,060 9783 mg), while the remaining 2 subjects were
administrated ibandronic acid (150 mg/month; cumulative dose
3360 mg) and neridronic acid (10 mg/month: cumulative dose:
4000 mg). Among oncologic patients, 6 subjects were treated with
zoledronic acid (4 mg/month; cumulative dose: 73.3 3.4), while
one subject was treated with denosumab (120 mg/month; cumula-
tive dose: 1200 mg).
Medication-Related Osteonecrosis of the Jaw
Characteristics
As reported in Supplemental Digital Content, Table 3, http://
links.lww.com/SCS/B191, all MRONJ lesions were symptomatic,
and exposed bone was detected in 6 cases (40%). Mandible was the
most affected site, accounting for 66.7% of cases, and according to
the AAOMS classification, 12 patients were classified as Stage III
and 3 patients as stage II.
Forty implants in total were evaluated (Supplemental Digital
Content, Table 4, http://links.lww.com/SCS/B191). In our sample,
MRONJ was present around 29 implants, while 11 implants (placed
in 7 patients) were not affected. Non-affected implants were almost
equally distributed in the mandible (6 implants) and in the maxilla
(5 implants). In 2 patients, MRONJ was present both around
implants and in another non-implant related site.
The mean number of affected implants in the mandible was
slightly higher than in the maxilla (2.1 and 1.6 respectively),
although not statistically significant.
Surgical Outcome
At 12-month follow-up, complete healing was obtained in
86.7% of cases, with 100% success for maxillary MRONJ. Two
cases affecting mandible were resistant to surgical therapy (Sup-
plemental Digital Content, Table 5, http://links.lww.com/SCS/
B191). Stratification indicated 100% disease resolution for all stage
II lesions, 83.3% disease resolution for stage III (10 subjects).
Histology
Histological analysis showed the presence of necrotic bone
tissue characterized by the presence empty osteocytic lacunae
and empty Haversian systems and Volkmann canals. Necrotic area
was surrounded by an infiltrate of neutrophils and plasma cells. In
the peripheral area was detected the presence of actinomycetes.
DISCUSSION
The present study reports the experience of our group in the
diagnosis and surgical treatment of peri-implant MRONJ. In our
study sample, MRONJ was more frequently developed in patients
under pharmacological treatment with alendronic acid for osteopo-
rosis and zoledronic acid in oncologic patients, with mandible being
more affected than the maxilla. Although spontaneous healing of
MRONJ lesions has been seldom reported in literature,10,11 medical
treatment with antimicrobial agents and surgery may be required
depending on ONJ stage. As reported on the AAOMS position
paper, stages I and II benefit from conservative management, while
stage III requires surgical debridement/resection to obtain longer
term palliation of infection and pain. However, if stage II is
refractory to conservative management, surgical debridement of
the affected bone is recommended to reduce soft tissue irritation.
Our results showed good performance of surgical treatment, with a
high percentage of MRONJ resolution. MRONJ surgical treatment
outcome has been reported in literature to be stage-dependent.1
Consistently with previous literature and AAOMS guidelines,
complete healing was observed in all Stage II MRONJ, while in
2 Stage III patients resolution was not achieved.
As reported by Oteri et al12 the management of ONJ patients
includes not only the general treatment of MRONJ in terms of pain
relief and prevention of the development of new areas of necrosis,
but also the preservation of patients’ quality of life (QoL). There-
fore, in these patients the resolution of acute infection and pain
provides a support to the management of MRONJ, leading to a
significant improvement of perceived QoL.
Current guidelines regarding the possible association between
MRONJ and implant positioning raise the issue of the impossibility
to establish a direct link due to a lack of data. Recently, it has been
claimed that implant placement, being a surgical procedure, is as
risky as tooth extraction. However, the presence of an implant itself
seems to be a risk factor for ONJ development.
Several case series report the percentage of MRONJ developed
around implants, either shortly after positioning or without apparent
causal relationship (Supplemental Digital Content, Table 6, http://
links.lww.com/SCS/B191).7,13,14
Goss et al report an effective risk of implant failure associated to
therapy with oral BPs, occurring both when positioning implants in
FIGURE 3. Surgical procedure. (A) Preoperative view of peri-implant MRONJ,
occlusal view: suppuration and inflammation are present around dental
implants. (B) Preoperative view of peri-implant MRONJ, lateral view: bony
defect around implants can be observed, with loss of keratinized gingiva and
partial exposure of the fixture and of mandibular bone. (C) After flap elevation,
MRONJ can be observed. (D) Mandibular bone after implant removal. (E)
Wound closure with resorbable suture thread and soft tissue repositioning. (F)
Removed implants and necrotic bone around the fixtures.
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patients under pharmacological treatment with BPs and in patients
starting therapy with BPs with previously integrated implants. In
particular, the issue of patients developing osteoporosis requiring
pharmacological treatment, with possible loss of implant integra-
tion, is raised.13
Lazarovici et al15 consider BRONJ development a late compli-
cation of implant therapy showing no direct relationship to surgery.
In this sense, it is advisable to perform long-term follow-up, and in
cases of BRONJ development to prescribe antibiotic therapy with
doxycycline 100 to 200 mg/d. Surgical treatment with implant
removal is reserved to antibiotic resistant symptoms.15 In our study
sample, surgery was performed after medical treatment with com-
bined antibiotics and professional oral hygiene. Moreover, surgical
treatment involved bone debridement and sequestrectomy in addi-
tion to implant removal.
Jacobsen et al highlighted a predominance of BRONJ localiza-
tion in the posterior region of the jaws, suggesting posterior implant
localization as a risk factor for BRONJ development, and describe a
histological pattern corresponding to inflammation and Actinomy-
ces infection.16
López-Cedrún et al recorded the presence of coexisting patho-
logic conditions and health-threatening habits, but due to limited
study sample firm conclusions could not be drawn.17 In our study,
we stratified patients depending on comorbidities and underlying
diseases, but did not find correlation with the onset of MRONJ due
to limited study sample. Further studies on larger populations are
therefore needed to better assess the role of coexistent pathologic
conditions.
Kwon et al18 report an average time of implant-related BRONJ
onset of 13 to 27 months after the beginning of BP therapy, with the
minority of patients considered as ‘‘implant surgery-triggered’’
BRONJ cases. Moreover, it is described the histologic aspect of
implant-related BRONJ lesions.18 In our sample, medium onset of
MRONJ was 67.7 36.1 months after treatment beginning. As
previous described by Marx and collaborators histologic analyses
show the presence of necrotic bone tissue characterized surrounded
by an infiltrate of neutrophils and plasma cells. In the peripheral
area was detected the presence of actinomycetes.14
Giovannacci et al suggest that increased risk of developing
MRONJ around implants may be related to the effect of antire-
sorptive drugs on bone remodeling. In fact, bone around implants is
subject to continuous modification, in particular when considering
implants loaded with prostheses. The inhibition deriving from
antiresorptive therapy thus may lead to MRONJ development also
in patients with osteointegrated implants.7
Troeltzsch et al19 highlight the possible role of peri-implantitis
as a risk factor for MRONJ development around dental implants,
being observed more frequently in patients with long treatment of
antiresorptive/antiangiogenic drug treatment. The improvement of
oral hygiene could play an important role in preventing MRONJ
onset in general and avoid the development of peri-implantitis
around dental implants, which seems to be a trigger factor for
peri-implant MRONJ.19
In our sample, MRONJ development was evaluated in patients
administered BPs and in 1 patient treated with Denosumab. A
previous case series by Pogrel and Ruggiero20 reported late implant
failure in patients treated with BPs or Denosumab, with bone
exposure around implants and development of a sequestrum.
The characteristics of our sample confirm the findings of other
authors, with the mandible being more affected than the maxilla and
an association with the administration of zoledronic and alendronic
acid.21
According to previous literature, MRONJ development around
implants was not related to apparent triggering factors. In a recent
meta-analysis by Stavropoulos et al, it is stated that peri-implant
MRONJ is not fully understood as a pathologic condition, hypothe-
sizing as concurring factor the reduction of bone remodeling and
subsequent vulnerability to infection.
Attempts have been made to stratify the risk of ONJ development
in patients undergoing pharmacological treatment with anti-resorp-
tive drugs. In a study by Peisker et al,22 the potential role of
serological bone turnover markers was investigated to evaluate
whether their variation could determine a higher risk of ONJ devel-
opment after oral surgical procedures. Although patients affected by
MRONJ showed decreased values of serum bone alkaline phospha-
tase (s-BAP), results did not reach statistical significance. However, a
potential role of serological biomarkers may be helpful in evaluating
the risk of MRONJ development in at-risk patients.
Considering surgical treatment, to the best of our knowledge we
are the first to report surgical outcome of Stage II/III peri-
implant MRONJ.
Relying on the experience deriving from previous studies on
MRONJ not involving dental implants, we applied a standardized
surgical protocol for the treatment of peri-implant MRONJ, obtain-
ing positive outcome in almost 90% of cases. In a work by Graziani
et al,23 resective surgery showed to be an effective approach to the
treatment of Stage II/III due to limited morbidity, while the outcome
of conservative surgery seemed less predictable. In our sample,
surgical approach involving implant removal and bone debridement
with sequestrectomy proved to be effective, by providing complete
healing in 86.7%, in agreement with other studies reporting the
clinical outcome of MRONJ surgery.
In particular, complete healing was observed in all Stage II
patients, while in Stage III surgical treatment was successful in
83.3% of cases. High success rate in patients with stage III ONJ
suggests that the presence of MRONJ limited to the peri-implant
area may potentially be a positive prognostic factor for surgical
treatment.
Our study is the second in literature to evaluate surgical outcome
in peri-implant MRONJ, although showing some differences with
the work of Lazarovici et al.15 In fact, while in their study surgical
treatment was reserved to antibiotic-resistant MRONJ, we per-
formed surgery in all patients after initial medical treatment.
However, the main limitation of our study is the retrospective
design. Further prospective studies are therefore needed to better
assess the impact of antiresorptive/antiangiogenic drugs on dental
implants and their relationship with MRONJ development. None-
theless, our results suggest a beneficial role of surgery in treating
peri-implant MRONJ and highlight the importance of monitoring
and prevention in patients under pharmacological treatment
with anti-resorptive/antiangiogenic drugs, in which peri-implant
MRONJ can develop also in absence of specific traumatic events.
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